John F. Seymour
Peter MacCallum Cancer Centre
781 Papers
5.1K Citations
John F. Seymour is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 96, co-authored 706 publications. Previous affiliations of John F. Seymour include Royal Children's Hospital & St. Vincent's Health System.
Chat about Author
Papers
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Stefan Peinert,John F. Seymour +1 more
TL;DR: In WM, serial measurements of the monoclonal IgM paraprotein level in an individual patient are accepted as a quantitative measure of disease burden, while in MM disease progression can occur in the absence of a paraprotein rise, characterized by an increase of the free light chains in the serum only ('light chain escape').
Targeting the BRAF pathway in haematological diseases
Matthew J Rees,Michael Dickinson,J. S. Paterson,Andrew Grigg,J. Moore,Piers Blombery,John F. Seymour +6 more
TL;DR: In this paper , the authors review the Australian experience of BRAF/MEK inhibitor therapy in rare haematological cancers, including hairy cell leukaemia, Erdheim-Chester disease and Langerhans cell histiocytosis.
Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
TL;DR: The history and current knowledge regarding BCL2 inhibition as therapy of CLL are discussed, and a number of small molecule inhibitors developed to mimic the function of the pro-apoptotic BH3-only proteins (BH 3-mimetics) demonstrate potent activity.
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Simon J. Harrison,Simon J. Harrison,Hang Quach,Emma Link,John F. Seymour,John F. Seymour,David Ritchie,David Ritchie,Sam A Ruell,Joanne Dean,Henry Januszewicz,Ricky W. Johnstone,Ricky W. Johnstone,Paul J Neeson,Michael Dickinson,Michael Dickinson,Jean Nichols,H. Miles Prince +17 more
TL;DR: The combination of romidepsin, bortezomib, and dexamethasone for the treatment of patients with multiple myeloma previously treated with > 1 prior therapy shows activity with manageable toxicity and warrants further evaluation.
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Michael L. Wang,Nirav N. Shah,Wojciech Jurczak,Pier Luigi Zinzani,Toby A. Eyre,Chan Yoon Cheah,Chaitra S. Ujjani,Youngil Koh,Koji Izutsu,James N. Gerson,Ian W. Flinn,Benoit Tessoulin,Alvaro J. Alencar,Shuo Ma,Ewa Lech-Marańda,Joanna M. Rhodes,Krish Patel,Jennifer A. Woyach,E. Lamanna,Yucai Wang,Constantine S. Tam,John F. Seymour,Talha Munir,Hirokazu Nagai,Francisco J. Hernandez-Ilizaliturri,Anita Kumar,Andrew D. Zelenetz,Preetesh Jain,Binoj Nair,Donald E. Tsai,Minna D. Balbas,Richard A. Walgren,Paolo Abada,Chunxiao Wang,Junjie Zhao,Anthony R. Mato +35 more